Bayer launches special access program for Leukine
Bayer HealthCare has announced that it will withdraw the current liquid formulation of Leukine (sargramostim) due to increased reportsof adverse reactions associated with the 500mcg vials containing EDTA (edetate disodium). While Bayer works to replace the current liquidformulation and reformulate Leukine to eliminate EDTA, it will establish a special access program for the lyophilized Leukine 250mcg vialwhich does not contain EDTA.
The special access program is designed to prioritize the supply of lyophilized Leukine for patients with acute myelogenousleukemia (AML) and those who are experiencing bone marrow transplantation engraftment failure or delay. Leukine is a recombinantgranulocyte-macrophage colony-stimulating factor (rhu GM-CSF) for use following induction chemotherapy in older adults with AML and inmultiple stem cell transplantation settings.
For more information call (888) 84BAYER or visit http://www.leukine.com.